The following is a summary of “Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging ...

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). A first-in-class ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo nodularis in the European Union, Galderma announced in a press release.

GSK's new long-acting drug candidate for severe asthma, depemokimab ... achieve a significant reduction in the annualised rate of moderate or severe exacerbations in the MATINEE trial in chronic ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

For this reason, ipratropium was not recommended in asthma, except in acute severe asthma management ... The first large study on unselected moderate asthmatics showed that tiotropium was as ...

EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.

The study showed that medicine used to help asthma patients for more than 20 years could lessen or prevent acute allergic ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...